1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
APRIL 1, 1997
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-14680 06-1047163
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
ONE KENDALL SQUARE, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 252-7500
Total number of page in document - 26
Exhibit Index located on page - 4
2
ITEM 5. OTHER.
------
In order to update the information previously filed with the Securities
and Exchange Commission at pages F-2 to F-17 to the Current Report of Genzyme on
Form 8-K (Commission File No. 0-14680) filed on February 4, 1997, Genzyme hereby
files as Exhibit 99.1 unaudited pro forma financial statements and the related
notes thereto for both Genzyme and Genzyme General Division (the "General
Division") giving effect to the acquisition by Genzyme of Genetrix, Inc.
("Genetrix") on May 1, 1996 (the "Genetrix Acquisition"), the acquisition of
Deknatel Snowden Pencer, Inc. ("DSP") on July 1, 1996 (the "DSP Acquisition"),
and the acquisition of Neozyme II (the "Neozyme II Acquisition") on December 6,
1996 (collectively, the "Acquisitions"). Pro forma condensed statements of
operations have been presented for both Genzyme and the General Division
assuming that the Acquisitions occurred as of January 1, 1996, using the
purchase accounting method. The historical Genzyme and General Division balance
sheets as of December 31, 1996, which are included in the Company's Annual
Report on Form 10-K, reflects the effect of the Genetrix Acquisition which was
completed on May 1, 1996, the DSP Acquisition which was completed on July 1,
1996, and the acquisition of Neozyme II which was completed on December 6,
1996. Therefore, pro forma balance sheets for Genzyme and the General Division
are not included herein.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
---------------------------------
(c) Exhibits.
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Unaudited pro forma statements of operations
(and related notes) for the year ended December
31, 1996 for Genzyme and the General
Division, giving effect to the Acquisitions.
Filed herewith.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 1, 1997 GENZYME CORPORATION
By:/s/ David J. McLachlan
------------------------------------
David J. McLachlan
Executive Vice President, Finance;
Chief Financial Officer
4
EXHIBIT INDEX
EXHIBIT SEQUENTIAL
NO. DESCRIPTION PAGE NO.
--- ----------- --------
99.1 Unaudited pro forma statements of operations (and related notes)
for the year ended December 31, 1996 for Genzyme and
the General Division, giving effect to the Acquisitions.
Filed herewith.